Olive Oil and 19% Lower Mortality in 92,383 U.S. Adults Over 28 Years

This 28-year prospective cohort study from Harvard tracked olive oil intake and mortality outcomes in 92,383 U.S. adults, published in the Journal of the American College of Cardiology. Higher olive oil consumption was associated with 19% lower all-cause mortality and 29% lower risk of dying from neurodegenerative disease. The study is one of the largest investigations to date of olive oil's long-term mortality association in a non-Mediterranean population.

Why This Study Matters

Most of the high-quality research on olive oil and cardiovascular outcomes was conducted in Mediterranean populations -- PREDIMED in Spain, EPIC-Spain, the Three-City study in France. The open question has always been whether the same benefits show up in adults whose habitual diet isn't built around olive oil to begin with. Americans consume about 1 kilogram of olive oil per person per year. Greeks consume 15 to 20 times that. Whether the dose-response curve holds outside the Mediterranean diet matrix wasn't established.

This study answered that question with the largest U.S. dataset available. The researchers used 28 years of follow-up data from two of the most rigorously maintained prospective cohorts in nutrition epidemiology: the Nurses' Health Study and the Health Professionals Follow-up Study. They tracked olive oil intake at four-year intervals, recorded 36,856 deaths, and ran the analysis against four major cause-of-death categories.

The result was a consistent association: higher olive oil intake was linked to lower mortality across all four categories, with the strongest effect in neurodegenerative disease deaths. That finding -- 29% lower risk -- is one of the largest reported in the olive oil literature for any single outcome.

How It Was Designed

The basics are in the study design bar above: 92,383 participants, 28 years of follow-up, two pooled prospective cohorts, Harvard T.H. Chan School of Public Health. A few methodological choices deserve highlighting.

Dietary intake was assessed by semi-quantitative food frequency questionnaire every four years, not just at baseline. This matters because dietary patterns drift over decades, and one-shot assessment from 1990 wouldn't have captured the actual cumulative exposure. The researchers used cumulative averaged intake rather than baseline-only data, which reduces measurement error and aligns the exposure variable more closely with biology.

The Cox proportional-hazards models adjusted for 27 covariates including age, ethnicity, BMI, smoking, physical activity, alcohol intake, family history of disease, hypertension, hypercholesterolemia, multivitamin use, total energy intake, and overall diet quality (Alternative Healthy Eating Index score). Critically, the analyses also adjusted for intake of other foods rich in monounsaturated fat. This isolates olive oil's specific association from the broader dietary pattern it usually travels with.

The substitution analyses are worth noting separately. Rather than just comparing high vs. low olive oil consumers, the researchers modeled what happens when 10 grams per day of other fats (margarine, butter, mayonnaise, dairy fat) are replaced with the equivalent amount of olive oil. This is closer to the practical question most readers actually have: not "should I eat more olive oil?" but "what if I swap one fat for another?"

What They Found

Comparing participants in the highest olive oil consumption category (more than 0.5 tablespoon per day, or more than 7 grams per day) to those who never or rarely consumed olive oil, the pooled hazard ratios were:

Outcome	Hazard Ratio (95% CI)	Risk Reduction	What It Measures
All-cause mortality	0.81 (0.78-0.84)	19% lower	Death from any cause
Cardiovascular mortality	0.81 (0.75-0.87)	19% lower	Heart disease, stroke, other CVD
Cancer mortality	0.83 (0.78-0.89)	17% lower	Death from any cancer
Neurodegenerative mortality	0.71 (0.64-0.78)	29% lower	Alzheimer's, Parkinson's, related
Respiratory mortality	0.82 (0.72-0.93)	18% lower	COPD, pneumonia, lung disease

Green indicates a favorable direction vs. low/no olive oil intake. All hazard ratios are statistically significant; 95% confidence intervals exclude 1.0.

The substitution analyses showed that replacing 10 grams per day of other fats with the equivalent amount of olive oil was associated with 8% to 34% lower risk of total and cause-specific mortality, depending on the fat replaced. Replacing margarine yielded the largest reductions; replacing dairy fat yielded the smallest. Substituting olive oil for other vegetable oils combined showed no significant association -- consistent with the idea that the specific advantage is over animal-derived and industrial fats, not over other plant oils.

Reading the Results

The four cause-specific outcomes group into mechanisms worth pulling apart.

Cardiovascular and respiratory mortality (19% and 18% lower). These two share an underlying biology: vascular inflammation and oxidative stress. Olive oil polyphenols -- particularly hydroxytyrosol and oleocanthal -- have been shown in RCTs to reduce oxidized LDL and inflammatory markers like CRP. The 2011 EFSA-authorized health claim for olive oil polyphenols specifically cites protection of blood lipids from oxidative damage. The cardiovascular signal in this study is consistent with the established mechanism.

Cancer mortality (17% lower). Less mechanistically settled. The most plausible pathways are anti-inflammatory effects, modulation of insulin-like growth factors, and direct effects of phenolic compounds on cancer cell signaling. Prior PREDIMED data showed lower breast cancer incidence with EVOO supplementation, which fits.

Neurodegenerative mortality (29% lower). The largest single effect in the study and the one most worth understanding. Multiple mechanisms have been proposed: hydroxytyrosol crosses the blood-brain barrier and reduces oxidative stress in neural tissue; oleocanthal has been shown to bind tau and amyloid-beta proteins in laboratory studies; chronic systemic inflammation is increasingly understood as a contributor to Alzheimer's and Parkinson's pathology. The 29% figure is large enough that it's worth noting the confidence interval (0.64-0.78) is also large, meaning the true effect could plausibly be anywhere from 22% to 36% lower. Either end of that range is clinically meaningful.

The dose threshold is also informative. The benefit emerged at consumption levels above 7 grams per day -- about half a tablespoon. That's roughly one-third of what a typical Mediterranean-diet study participant consumes, suggesting the dose-response curve may not require Mediterranean-level intake to show measurable benefit.

What Didn't Change

Olive oil intake was not associated with significantly lower mortality when compared to other vegetable oils combined. This is the cleanest finding for what the study does NOT support: the data don't establish olive oil as superior to other plant oils for mortality outcomes. The comparison that drives the benefit is olive oil vs. animal fats and processed fats like margarine -- not olive oil vs. canola or sunflower oil.

The study is also observational, not interventional. It cannot prove that consuming more olive oil causes lower mortality. The associations could reflect residual confounding by overall diet quality, socioeconomic factors, or health-conscious behavior patterns that olive oil consumers tend to share. The 27-covariate adjustment reduces but does not eliminate this possibility.

Broader Context

This study extends a body of evidence that includes the original PREDIMED trial (2018 republished, NEJM), which showed a 30% reduction in major cardiovascular events with a Mediterranean diet supplemented with extra-virgin olive oil. PREDIMED was a randomized controlled trial in Spain. The Harvard cohort study is observational and runs in a non-Mediterranean population, which is exactly why it adds rather than duplicates: it tests whether the PREDIMED-era findings generalize to U.S. adults eating their usual diets.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at a daily intake of 5 mg of hydroxytyrosol and its derivatives. This study did not measure polyphenol intake directly, but the dose threshold for mortality benefit (more than 7 g/day of olive oil) is at the low end of what would supply the EFSA-recognized polyphenol dose, depending on the oil's polyphenol concentration.

What makes this 2022 analysis worth highlighting in the broader literature is scale and duration. 92,383 participants tracked for 28 years across two cohorts is one of the largest and longest-running data sets in olive oil epidemiology. The cause-specific breakdown -- and especially the neurodegenerative finding -- is one of the strongest signals in the literature for olive oil's potential beyond cardiovascular health.

Related Research

Continue exploring olive oil and polyphenol science:

• Olive Oil Linked to 28% Lower Dementia Death in 92,383 Adults
• Olive Oil and 14% Lower CV Risk in 90,000+ US Adults
• Italian Cohort: Olive Oil Linked to Lower Cancer, CV and All-Cause Mortality

Source: View the original study on PubMed

Olivea's Dosage

This study identified mortality benefit beginning at more than 7 grams per day of olive oil -- roughly half a tablespoon. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams, comfortably above the study threshold. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.